argenex SE $ARGX Shares Newly Purchased by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC purchased a new position in argenex SE (NASDAQ:ARGX) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,000 shares of the company’s stock, valued at approximately $1,918,000.

A number of other hedge funds also recently modified their holdings of the business. GAMMA Investing LLC raised its holdings in argenex by 31.5% during the 3rd quarter. GAMMA Investing LLC now owns 459 shares of the company’s stock worth $440,000 after buying an additional 110 shares during the period. Farther Finance Advisors LLC raised its stake in shares of argenex by 3.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 378 shares of the company’s stock worth $363,000 after purchasing an additional 13 shares in the last quarter. Valeo Financial Advisors LLC lifted its stake in argenex by 6.2% in the third quarter. Valeo Financial Advisors LLC now owns 1,144 shares of the company’s stock valued at $1,097,000 after acquiring an additional 67 shares during the last quarter. QRG Capital Management Inc. grew its holdings in argenex by 24.6% during the second quarter. QRG Capital Management Inc. now owns 1,907 shares of the company’s stock worth $1,769,000 after purchasing an additional 377 shares during the period. Finally, Envestnet Portfolio Solutions Inc. boosted its stake in shares of argenex by 12.7% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 365 shares of the company’s stock worth $339,000 after acquiring an additional 41 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Down 1.1%

NASDAQ:ARGX traded down $9.22 during trading hours on Tuesday, hitting $803.08. 141,913 shares of the company’s stock traded hands, compared to its average volume of 344,708. argenex SE has a 52 week low of $661.85 and a 52 week high of $1,072.75. The firm has a market cap of $50.24 billion, a P/E ratio of 30.86, a P/E/G ratio of 0.86 and a beta of 0.44. The business’s fifty day simple moving average is $959.56 and its two-hundred day simple moving average is $878.44.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 earnings per share for the quarter, topping the consensus estimate of $5.86 by $1.46. The company had revenue of $1.54 billion for the quarter, compared to analysts’ expectations of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 43.59%. On average, analysts expect that argenex SE will post 28.83 EPS for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on ARGX. Citigroup increased their price target on shares of argenex from $1,152.00 to $1,182.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Truist Financial boosted their price objective on shares of argenex from $1,030.00 to $1,095.00 and gave the company a “buy” rating in a research report on Tuesday, August 18th. Piper Sandler raised their target price on shares of argenex from $1,075.00 to $1,215.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. The Goldman Sachs Group reiterated a “buy” rating on shares of argenex in a report on Friday, September 25th. Finally, BNP Paribas Exane started coverage on shares of argenex in a report on Monday, June 22nd. They set an “outperform” rating and a $1,219.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,155.05.

argenex Company Profile

argenx SE (NASDAQ:ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company combines antibody engineering technologies with disease biology to discover medicines that target the underlying mechanisms of immune-mediated disorders.

argenx’s leading product is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo in the United States. The therapies are designed to reduce disease-causing immunoglobulin G (IgG) antibodies by targeting the neonatal Fc receptor (FcRn).